Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.67) EPS and Q4 2025 earnings at ($0.68) EPS.

A number of other research analysts also recently commented on ZNTL. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a report on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $3.05 on Friday. The firm has a market capitalization of $217.34 million, a P/E ratio of -1.22 and a beta of 1.74. The business’s 50-day moving average is $3.42 and its two-hundred day moving average is $5.33. Zentalis Pharmaceuticals has a 1 year low of $2.66 and a 1 year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. On average, analysts expect that Zentalis Pharmaceuticals will post -2.76 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Paloma Partners Management Co purchased a new position in Zentalis Pharmaceuticals during the third quarter worth $37,000. Anfield Capital Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at $40,000. Aigen Investment Management LP purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at $41,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Zentalis Pharmaceuticals during the third quarter valued at about $48,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.